We have assembled a team with significant expertise and a proven track record in discovering and developing drug candidates targeting liver diseases, including hepatitis C. We are applying the same innovative thinking to our HBV programs that members of our management team have successfully applied to developing the hepatitis C cure Sovaldi® − the most successful drug launch in history.
In addition to our robust HBV pipeline and proven management team, we have a strong financial position that is further supported by our equity investment in Genevant Sciences and our royalty entitlement on Alnylam’s ONPATTRO™ (patisiran), approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hereditary ATTR amyloidosis with polyneuropathy -- ONPATTRO is enabled by our Lipid Nanoparticle (LNP) delivery technology.
We have licensed our Lipid Nanoparticle (LNP) and ligand conjugate delivery technologies to several industry partners, allowing us to focus in one therapeutic area - HBV. Our partnered delivery technologies have been proven in RNA interference (RNAi) therapeutic development and represent opportunity in all applications of nucleic acid delivery to the liver. We see significant value in the collaborations Arbutus has established to date, and will continue to work closely with, and support, our partners.